Virtual Library
Start Your Search
M.R. Roglic
Author of
-
+
P1.04 - Poster Session with Presenters Present (ID 456)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Pulmonology
- Presentations: 1
- Moderators:
- Coordinates: 12/05/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P1.04-022 - Use of Alternative Therapy in Patients with Lung Cancer (ID 6212)
14:30 - 15:45 | Author(s): M.R. Roglic
- Abstract
Background:
Background: Lung cancer has the highest mortality among all malignant diseases due to advanced stage of diseases at diagnosis, but also due to modest response to therapy. For that reasons an increasing proportion of population use alternative therapy. Most often those are drugs that are alleged immunomodulators However, for systemically administered complementary and alternative medicine (CAM), there are significant risks of adverse drug interactions with conventional treatments, which may result in either increased drug toxicity or therapeutic failure.
Methods:
Methods: We performed a retrospective analysis of alternative therapies used during oncology treatment in lung cancer. Data were collected from medical documentation. Total of 246 patients diagnosed with lung cancer at Department of pulmonary diseases Jordanovac were tracked during a two-year period. General information, sociodemographic characteristics and alternative therapies were extractes from documentation and statistically analised.
Results:
Results: Total of 76 out of 246 patients (31%) admitted to using alternative therapy. Women use it more often than male (38% vs 28%). No difference was observed according to age o geographic location. Yet there was a small, but significant difference according to level of education. Among patient with university degree 36% used alternative therapy in contrast to 30% among those with high school education. Use of chemotherapy and advanced stage of disease correlated with more frequent CAM use (58% vs 42%). Most often used alternative therapy was aronia (46%) and then cannabis and its derivatives (mostly oil) in 36% of patients, while beta-glucan (11%) and other comprised smaller percentages.
Conclusion:
Conclusion: Use of alternative therapies is increasing among patients with lung cancer and it is imperative for physicians to know about this. So far there is no scientific or clinical evidence for positive effects of this therapy, but it is known that it can collide with chemotherapy. Because of that it is imperative to expand our knowledge of use of alternative therapy, as well as its effects.
